JORGE DIMARTINO, M.D.
Medical Practice at Welch Rd, Palo Alto, CA
License number
California G080354
Category
Medical Practice
Type
Pediatric Hematology-Oncology
Address
Address
2
725 Welch Rd, Palo Alto, CA 94304
1610 Fairway Dr, Belmont, CA 94002
1610 Fairway Dr, Belmont, CA 94002
Phone
(650) 723-5535
Organization information
See more information about JORGE DIMARTINO at bizstanding.comJorge Dimartino MD,PHD
725 Welch Rd, Palo Alto, CA 94304
Industry:
Pediatric Oncologist
Phone:
(650) 497-8000 (Phone)
Jorge Fernando Dimartino
Professional information
Dr. Jorge Dimartino, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
Lucille Packard Children's Hospital
1000 Welch Rd STE 300, Palo Alto 94304
(650) 497-8953 (Phone)
725 Welch Rd, Palo Alto 94304
(650) 723-5535 (Phone)
1000 Welch Rd STE 300, Palo Alto 94304
(650) 497-8953 (Phone)
725 Welch Rd, Palo Alto 94304
(650) 723-5535 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 1998, Pediatrics, 1996
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of California, San Diego, School Of Medicine
Graduated: 1993
Lucile Packard Chldns Hospital At Stanford
Graduated: 1994
Graduated: 1996
Stanford U/Packard Chldns Hospital
University Of California, San Diego, School Of Medicine
Graduated: 1993
Lucile Packard Chldns Hospital At Stanford
Graduated: 1994
Graduated: 1996
Stanford U/Packard Chldns Hospital
Methods For Treating Cancers Using Oral Formulations Of Cytidine Analogs
US Patent:
2013010, May 2, 2013
Filed:
Oct 31, 2012
Appl. No.:
13/665778
Inventors:
Aaron N. Nguyen - San Jose CA, US
Jorge DiMartino - Belmont CA, US
Jorge DiMartino - Belmont CA, US
Assignee:
Celgene Corporation - Summit NJ
International Classification:
A61K 31/706, A61P 35/00
US Classification:
514 43
Abstract:
Provided herein are methods for treating subjects having a cancer, such as a relapsed or refractory solid tumor, wherein the method comprises administering to the subject a cytidine analog. In certain of the methods, the cytidine analog is administered alone or in combination with one or more anti-cancer agents. Also provided are methods for using a cytidine analog, to treat diseases and disorders including disorders related to abnormal cell proliferation, hematologic disorders, and immune disorders, among others. In certain of the methods, the cytidine analog is formulated in an oral dosage form and administered orally.